4-Ethyl-3-Methyl-N-[2-[4-[(4-Methylcyclohexyl)Carbamoylsulfamoyl]Phenyl]Ethyl]-5-Oxo-2H-Pyrrole-1-Carboxamide

Achieving blend uniformity for glimepiride at unit doses of 1 mg, 2 mg, and 4 mg within a direct compression framework requires geometric dilution of the active with a pre-sieved directly compressible excipient matrix—typically a combination of spray-dried lactose monohydrate (FlowLac® 100), microcrystalline cellulose (Avicel® PH-102), and pregelatinized starch. Glimepiride constitutes 0.5% to 3.5% w/w of the core tablet mass, depending on the target label claim and functional tablet weight; for a 100 mg core bearing 1 mg of active, the drug load is 1.0% w/w, rising to 3.2% w/w in a 125 mg tablet with 4 mg strength. A process overage of 2–3% is applied to the glimepiride charge to compensate for electrostatic losses to blender surfaces and feed hopper walls, as justified in the pharmaceutical development report per ICH Q8(R2). The premix is passed through a 500 μm oscillating granulator or comil equipped with a round impeller and an equivalent mesh screen to de-lump agglomerates before transfer to a 600-litre bin blender or twin-shell V-blender for final low-shear mixing with sodium starch glycolate (2–4% w/w) and colloidal silicon dioxide (0.5% w/w). Magnesium stearate is introduced at 0.3–0.6% w/w as a boundary lubricant and tumbled for 2–3 minutes only; over-lubrication exceeding 5 minutes at 25 rpm has been shown on a 47-station Fette 1200i rotary press operating at 80 000 tablets per hour to retard dissolution below the Q=80% threshold in 30 minutes due to hydrophobic film formation on excipient surfaces. Compression runs employ 6 mm or 7 mm round flat-faced bevel-edge tooling with a target hardness of 4–8 kP and friability <0.5% after 100 rotations in a Pharmatron tester. Visible picking on the upper punches has been documented at compression forces above 12 kN when die-wall temperature exceeds 35 °C, necessitating dehumidified process air conditioned to 20–25 °C and RH ≤45%. Environmental excursions above RH 55% cause measurable increases in glimepiride sticking propensity due to surface adsorption of moisture onto the micronized particles, as confirmed by gravimetric vapour sorption profiles showing a 0.3% mass uptake at 50% RH. Compliance is demonstrated against USP General Chapters <905> Uniformity of Dosage Units and <711> Dissolution, the specific USP Glimepiride Tablets monograph, Ph.Eur. monograph 2256 with its identical paddle dissolution condition (Apparatus 2, 75 rpm, 900 mL pH 7.8 phosphate buffer, Q=80% at 30 min), and ICH M7(R2) for control of mutagenic impurities, specifically the sulfonamide-related impurities arising from the synthesis pathway. The terminal dosage form is a non-functional film-coated immediate-release tablet using an Opadry® II aqueous coating system applied to a weight gain of 2–3% in a perforated side-vented coating pan, with laser-etched identification codes applied post-coating.

What Limits High-Shear Wet Granulation End-Point Consistency for Glimepiride Formulations?

In production campaigns where the active pharmaceutical ingredient exhibits a broad particle-size distribution—spanning a d10 of 2 μm to a d90 of 45 μm as determined by laser diffraction (Malvern Mastersizer)—direct compression may fail content uniformity criteria (acceptance value >15.0 for single-stage testing per <905>), driving the need for wet mass granulation. Aqueous granulation fluids containing polyvinylpyrrolidone (PVP K30, 3–5% w/w of dry granulate) or partially pregelatinized starch (Starch 1500, 5–8% w/w) are metered into a Diosna P600 high-shear mixer at an impeller tip speed of 5–7 m/s and chopper speed of 1500–1800 rpm; granulation end-point is evaluated by impeller power consumption curves and a near-infrared probe measuring moisture content at an inflection point corresponding to 13–15% w/w water. Over-wetting beyond 16% moisture generates stubborn lumps that survive wet-milling through a 3.0 mm screen and subsequently yield a final dry granule fraction with poor disintegration at high hardnesses. The critical thermal constraint emerges during fluid-bed drying in a Glatt WSG-120 unit, where an inlet air temperature exceeding 60 °C for more than 40 minutes accelerates the formation of degradation impurity C (3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylic acid), which is controlled at NMT 0.2% per the USP monograph; consequently, drying is conducted at an inlet temperature of 50–55 °C until an LOD of 1.0–2.0% is reached, typically within 30 minutes. The dried granulate is milled through a Quadro Comil U20 with a 0.8 mm rasp screen at 1500 rpm, then blended with croscarmellose sodium (3% w/w, extra-granular) and magnesium stearate (0.5% w/w) for 2 minutes in a bin blender. Compression is performed on a Korsch XL 400 press with 8 mm standard concave tooling, maintaining a main compression force between 8 and 15 kN to achieve a tablet hardness of 6–10 kP without capping. The glimepiride load in the final core may range from 0.3% to 2.5% w/w because the wet mass binder adds bulk, expanding total core weight to 150–250 mg. Terminal dosage forms are film-coated immediate-release tablets that must comply with the dissolution acceptance criteria of USP Glimepiride Tablets (NLT 80% Q in 30 min) and Ph.Eur. monograph 2256, as well as the ICH Q3D guideline for elemental impurities, with special attention to palladium residues from hydrogenation steps and nickel from catalyst preparation. Guidance from FDA’s SUPAC-IR/MR provides the framework for post-approval changes to the granulation process.

Bilayer Compression Tooling and Granulation Strategy in Glimepiride/Metformin HCl FDC Tablets

Fixed-dose combinations coupling glimepiride at 1–2 mg with metformin hydrochloride at 500 mg or 1000 mg are manufactured as bilayer tablets wherein the glimepiride layer weighs only 50–80 mg and the metformin layer accounts for 650–1100 mg, creating a pronounced 10:1 layer-weight differential that directly challenges compaction uniformity and interlayer adhesion. The low-dose layer is typically prepared by wet granulation of glimepiride with lactose monohydrate, microcrystalline cellulose, and PVP K30 using a top-spray fluid-bed granulator for aqueous binder application, producing a free-flowing granulation with a d50 of 120–180 μm; glimepiride represents 1.5% to 4.0% w/w of this layer. The metformin layer, in contrast, is roll-compacted from a blend containing 85–93% w/w metformin HCl, microcrystalline cellulose, and povidone, then milled and lubricated; direct compression of the high-dose metformin fraction is generally avoided due to poor flow and die-fill inconsistency at high press speeds. Bilayer compression is performed on a rotary press equipped with an automatic weight control system for the first layer and a second-layer filling cam with pre-compression capability—the Fette 3090i or Korsch XM 12 are representative industrial machines. The first layer is pre-compressed at 8–12 kN, forming a flat, coherent mass into which the glimepiride granulation is filled and then main-compressed at 15–25 kN. Layer splitting during downstream coating or film-coating pan attrition is a documented failure mode when the pre-compression force is insufficient to create a bonding interface; process analytical technology integrating layer capacitance probing helps verify interfacial robustness in real time. Tablet hardness is maintained at 10–16 kP, and the bilayer units are film-coated with Opadry® to 3% weight gain. Regulatory compliance is anchored to the USP monograph for Glimepiride and Metformin Hydrochloride Tablets, which imposes dissolution tests in pH 6.8 phosphate buffer for metformin and pH 7.8 for glimepiride using a paddle at 50 rpm and 75 rpm respectively; additionally, ICH M7(R2) limits for nephrotoxic N-nitroso impurities in metformin-containing products apply, requiring validated LC-MS/MS methods with detection thresholds of ≤0.03 ppm for N-nitrosodimethylamine (NDMA). The finished product is an ovaloid bilayer tablet with immediate-release characteristics for both actives.

When Pioglitazone Hydrochloride and Glimepiride Are Co-formulated in a Capsule

Capsule filling has been adopted as an alternative to bilayer compression for the combination of pioglitazone HCl (15–45 mg base equivalent) with glimepiride (1–4 mg) to circumvent the complexity of maintaining tablet hardness while ensuring rapid disintegration for two pH-dependent solubility profiles. Glimepiride, exhibiting poor aqueous solubility below pH 6, requires micronization to a d90 <15 μm and must be preblended with an alkaline bulking agent—commonly dibasic calcium phosphate anhydrous (20–30% w/w of the capsule fill)—to elevate the local interfacial pH during dissolution. The low-dose glimepiride fraction, representing 0.15% to 0.7% w/w of the total fill weight of 400–600 mg in a size 0 or size 1 hard gelatin capsule, is first geometrically diluted with a portion of the filler and passed twice through a 0.5 mm mesh sieve to break down agglomerates. Pioglitazone HCl, typically at 3–10% w/w of the fill, is dry-mixed with the remaining microcrystalline cellulose and croscarmellose sodium (2–4% w/w) before charging the entire final blend into a dosing disc capsule filler (Bosch GKF 1500 or MG2 Planeta). The fill weight is targeted to achieve a plug density that allows disintegration times below 10 minutes per <2040> Disintegration; powder bridging in the dosing disc has been corrected by maintaining blend moisture content below 2.5% and increasing the number of tamping pins to 5 stations. Dissolution conditions are specified individually: glimepiride release is assessed in pH 7.8 phosphate buffer using USP Apparatus 2 at 75 rpm (NLT 80% at 30 min), while pioglitazone is assessed in pH 2.0 HCl with paddle at 50 rpm (NLT 75% at 45 min). Compliance with ICH Q3A/B for organic impurities addresses both glimepiride-related sulfonamide degradants and pioglitazone-related ketone intermediates. Terminal dosage form is a hard gelatin capsule printed with a pharmaceutical-grade ink, sometimes banded to prevent tampering.

Masking the intrinsic bitter taste of glimepiride for an orally disintegrating tablet (ODT) platform demands a polymeric barrier that remains intact in the oral cavity (pH 6.5–7.2) and dissolves rapidly upon reaching the gastric environment (pH <5). Amino methacrylate copolymer (Eudragit® E PO) is dissolved in a binary acetone/isopropanol solvent system and applied to glimepiride crystals or granule cores using a Würster bottom-spray fluid-bed process (Glatt GPCG 3 or equivalent), with an inlet air temperature of 35–40 °C and a product bed temperature not exceeding 32 °C to prevent polymer stickiness. A coating weight gain of 15–25% w/w is required to consistently block tastant migration during the 30-second oral residence window, confirmed by an electronic tongue and human gustatory panel trials. The coated particles, comprising 8–12% w/w of the final ODT blend with an effective glimepiride content of 0.8–2.5% w/w, are combined with a superdisintegrant—typically crospovidone (5–8% w/w) or a co-processed croscarmellose sodium-crospovidone system—and a directly compressible mannitol-sorbitol matrix containing a sweetener (sucralose 0.5% w/w) and a flavour. Compression on a rotary press using 8 mm flat-faced bevel-edge punches produces tablets with a breaking force of 15–30 N, sufficient to withstand packaging stress while allowing in-vitro disintegration below 30 seconds in a low-volume (5 mL) simulated salivary fluid at 37 °C, as per the adapted Ph.Eur. 2.9.1 method for orodispersible tablets. Special attention is given to package integrity: if the coated particle fraction exceeds 15% w/w, friability measured by a friabilator at 4 minutes tends to exceed 1.0%, necessitating a cold-form blister with a desiccant. The regulatory framework is drawn from FDA Guidance for Orally Disintegrating Tablets, the USP General Chapter <701> Disintegration, and European Pharmacopoeia monograph 1806 for orodispersible tablets, along with impurity profiling mandates of ICH Q3B. Terminal dosage form is a round, flat-faced ODT blister-packed in peelable aluminium laminate pouches with a 2-year shelf-life under controlled room temperature.

Published monographs and dissolution test parameters evolve with pharmacopoeial updates, yet the core performance standards for glimepiride tablets remain methodologically stable. The USP Glimepiride Tablets monograph prescribes Turbidometric or HPLC identity testing, dissolution using Apparatus 2 (paddle) at 75 rpm in 900 mL of pH 7.8 phosphate buffer with Q=80% dissolved in 30 minutes, and an acceptance value for uniformity of dosage units derived from 10 or 30 units. Ph.Eur. 2256 aligns dissolution conditions and additionally specifies impurity A (sulfonamide) at NMT 0.2%, impurity C at NMT 0.2%, and total impurities at NMT 0.5%. For bilayer FDC tablets, the USP monographs for glimepiride and metformin hydrochloride tablets impose a discriminatory two-tier dissolution test where metformin release in pH 6.8 phosphate buffer at 50 rpm and glimepiride release at 75 rpm in pH 7.8 are independently reported, requiring NLT 85% metformin dissolved in 30 minutes and NLT 80% glimepiride dissolved in 30 minutes. Analytical method transfers to contract laboratories frequently reveal inter-laboratory variance of ±3% in glimepiride content due to the sensitivity of the HPLC method to column temperature fluctuations, necessitating a thermostatted column compartment maintained at 25±1 °C and use of a 100% mass-balanced reference standard. Equipment qualification packages must address the cross-contamination risk associated with sulfonylurea trace residues, validated through a cleaning validation protocol achieving carryover levels <10 ppm of glimepiride on shared product-contact surfaces.